Catal­ent bags a Ger­man stem cell de­vel­op­er to build its next-gen ther­a­peu­tics wing

An­oth­er day, an­oth­er ac­qui­si­tion for CD­MO gi­ant Catal­ent. The New Jer­sey firm has now bought out Ger­many’s Rhein­Cell Ther­a­peu­tics, a spe­cial­ist in hu­man in­duced pluripo­tent stem cells, to build out its next-gen ther­a­pies wing.

The Ger­man com­pa­ny is based in Lan­gen­feld, out­side of Düs­sel­dorf, around 2.5 hours’ dri­ve from Catal­ent’s cam­pus for cell and gene ther­a­py in Gos­selies, Bel­gium, al­low­ing for ef­fi­cient trans­fer. Af­ter the deal clos­es, which is ex­pect­ed be­fore the end of 2021, Rhein­Cell’s em­ploy­ees will join Catal­ent’s cell and gene ther­a­py op­er­a­tions. The ac­qui­si­tion helps Catal­ent build up­on its cur­rent cell ther­a­py de­vel­op­ment and man­u­fac­tur­ing ca­pa­bil­i­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER